Effects of the novel antipsychotic agent 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy}-3,4-dihydro-2(1H)- quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 1, 1996, Pages 137-143

  Inoue, Tsutomu ^a   Domae, Mariko ^a   Yamada, Katsushi ^b   Furukawa, Tatsuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; PROLACTIN; RESERPINE; TALIPEXOLE;

ADENOHYPOPHYSIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; HYPERPROLACTINEMIA; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PSYCHOSIS; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; AZEPINES; ESTRADIOL; HALOPERIDOL; MALE; PIPERAZINES; PITUITARY GLAND, ANTERIOR; PROLACTIN; QUINOLONES; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RESERPINE;

EID: 0030430029     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. ANDÉN, N. -E. AND GRABOWSKA-AND'EN, M.: B-HT 920 is a full agonist at both pre- and postsynaptic D-2 dopamine receptors. J. Neural Transm. 79: 209-214, 1990.
2. ANDÉN, N. -E., GRABOWSKA-AND'EN, M. AND LILJENBERG, B.: On the presence of autoreceptors on dopamine neurons in different brain regions. J. Neural Transm. 57: 129-137, 1983.
3. ARNT, J. AND HYTTEL, J.: Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxydopamine lesions and by chronic reserpine treatment in rats. J. Neural Transm. 60: 205-223, 1984.
4. BEN-JONATHAN, N.: Dopamine: A prolactin-inhibiting hormone. Endocr. Rev. 6: 564-589, 1985.
5. BEN-JONATHAN, N., OLIVER, C., WEINER, H. J., MICAL, R. S. AND PORTER, J. C.: Dopamine in hypophysial portal plasma of the rat during the estrous cycle and throughout pregnancy. Endocrinology 100: 452-458, 1977.
6. 2 dopamine receptor cDNA. Nature (Lond.) 336: 783-787, 1988.
7. CROW, T. J., JOHNSTONE, E. C., LONGDEN, A. AND OWEN, F.: Dopamine and schizophrenia. In Advances in Biochemical Psychopharmacology, ed. by P. J. Roberts, G. N. Woodruff and L. L. Iversen, Vol. 19, pp. 301-309, Raven Press, New York, 1978.
8. DEMAREST, K. T. AND MOORE, K. E.: Comparison of dopamine synthesis regulation in the terminals of nigrostriatal, mesolimbic, tuberoinfundibular and tuberohypophyseal neurons. J. Neural Transm. 46: 263-277, 1979.
9. DOMAE, M., YAMADA, K., HANABUSA, Y., MATSUMOTO, S. AND FURUKAWA, T.: Decrease of prolactin secretion via stimulation of pituitary dopamine D-2 receptors after application of talipexole and SND 919. Eur. J. Pharmacol. 179: 75-82, 1990.
10. DRUKARCH, B. AND STOOF, J. C.: D-2 dopamine autoreceptor selective drugs: Do they really exist? Life Sci. 47: 361-376, 1990.
11. 2short receptors. In Dopamine Receptors and Transporters: Pharmacology, Structure, and Function, ed. by H. B. Niznik, pp. 323-342, Marcel Dekker, Inc., New York, 1994.
12. GIBBS, D. M. AND NEILL, J. D.: Dopamine levels in hypophysial stalk blood in the rat are sufficient to inhibit prolactin secretion in vivo. Endocrinology 102: 1895-1900, 1978.
13. GUDELSKY, G. A. AND PORTER, J C.: Release of newly synthesized dopamine into the hypophysial portal vasculature of the rat. Endocrinology 104: 583-587, 1979.
14. GUDELSKY, G. A. AND PORTER, J. C.: Sex-related difference in the release of dopamine into hypophysial portal blood. Endocrinology 109: 1394-1398, 1981.
15. GUTTMAN, M.: Dopamine receptors in neurological disease. In Dopamine Receptors and Transporters: Pharmacology, Structure, and Function, ed. by H. B. Niznik, pp. 595-608, Marcel Dekker, Inc., New York, 1994.
16. HJORTH, S., CLARK, D. AND CARLSSON, A.: Dopamine (DA) autoreceptor efficacy of 3-PPP enantiomers after short-term synaptic DA deprivation. Eur. J. Pharmacol. 152: 207-215, 1988.
17. KEBABIAN, J. W. AND CALNE, D. B.: Multiple receptors for dopamine. Nature (Lond.) 277: 93-96, 1979.
18. 2 receptor antagonistic activity. J. Pharmacol. Exp. Ther. 274: 329-336, 1995.
19. MØLLER NIELSEN, I., CHRISTENSEN, A. V. AND HYTTEL, J.: Adaptational phenomena in neuroleptic treatment. In Advances in Biochemical Psychopharmacology, ed. by P. J. Roberts, G. N. Woodruff and L. L. Iversen, Vol. 19, pp. 267-274, Raven Press, New York, 1978
20. NOMIYAMA, T., SASA, M. AND TAKAORI, S.: D-2 receptor-mediated inhibition by a substituted quinolinone derivative, 7-{3-[4-(2,3-dimethylphenyl)piperazinyl]-propoxy}-2(1H)-quinolinone (OPC-4392), of dopaminergic neurons in the ventral tegmental area. Life Sci. 47: 761-769, 1990.
21. 3H]spiperone-binding sites in ovariectomized rats. Endocrinology 114: 2306-2311, 1984.
22. 3H]dopamine in rat basal hypothalamus and neurointermediate lobe of the pituitary gland. Brain Res. 413: 205-212, 1987.
23. PULVIRENTI, L. AND KOOB, G. F.: Dopamine receptor agonists, partial agonists and psychostimulant addiction. Trends Pharmacol. Sci. 15: 374-379, 1994.
24. SASA, M., OHNO, Y. AND TAKAORI, S.: Presynaptic inhibition of excitatory input from the substantia nigra to caudate nucleus neurons by a substituted quinolinone derivative, 7-{3-[4-(2,3-dimethylphenyl)piperazinyl]propoxy}-2(1H)-quinolinone (OPC-4392). Life Sci. 43: 263-269, 1988.
25. SEEMAN, P.: Dopamine receptors in schizophrenia. In Dopamine Receptors and Transporters: Pharmacology, Structure, and Function, ed. by H. B. Niznik, pp. 541-549, Marcel Dekker, Inc., New York, 1994.
26. SEEMAN, P., LEE, T., CHAU-WONG, M. AND WONG, K.: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature (Lond.) 261: 717-718, 1976.
27. SIBLEY, D. K., GONZALEZ, A. M., BURGESS, L. H., MAX, S. I., ATKINSON, B. N. AND ZHANG, L. -J.: Pharmacological characterization of OPC-14597, a novel anti-psychotic agent, using cloned dopamine and serotonin receptors. Neuropschychopharmacology 10: suppl. II, 252S, 1994.
28. 3) as a target for neuroleptics. Nature (Lond.) 347: 146-151, 1990.
29. 4 receptor with high affinity for the antipsychotic clozapine. Nature (Lond.) 350: 610-614, 1991.
30. YASUDA, Y., KIKUCHI, T., SUZUKI, S., TSUTSUI, M., YAMADA, K. AND HIYAMA, T.: 7-{3-[4-(2,3-dimethylphenyl)piperazinyl]propoxy}-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist. Life Sci. 42: 1941-1954, 1988.
31. WINER, B. J.: Statistical Principles in Experimental Design. McGraw-Hill, New York, 1971.